Robot-Assisted Prostate-Specific Membrane Antigen-Radioguided Surgery in Primary Diagnosed Prostate Cancer

Autor: William Gondoputro, Matthijs J Scheltema, Alexander Blazevski, Paul Doan, James E. Thompson, Amer Amin, Bart Geboers, Shikha Agrawal, Amila R. Siriwardana, Pim J. van Leeuwen, Matthias N van Oosterom, Fijs N van Leeuwen, Louise M. Emmett, Phillip D Stricker
Přispěvatelé: Urology, Radiology and nuclear medicine
Jazyk: angličtina
Rok vydání: 2022
Předmět:
Zdroj: Journal of nuclear medicine, 63(11), 1659-1664. Society of Nuclear Medicine Inc.
Gondoputro, W, Scheltema, M J, Blazevski, A, Doan, P, Thompson, J E, Amin, A, Geboers, B, Agrawal, S, Siriwardana, A, van Leeuwen, P J, van Oosterom, M N, van Leeuwen, F W B, Emmett, L & Stricker, P D 2022, ' Robot-Assisted Prostate-Specific Membrane Antigen-Radioguided Surgery in Primary Diagnosed Prostate Cancer ', Journal of nuclear medicine : official publication, Society of Nuclear Medicine, vol. 63, no. 11, pp. 1659-1664 . https://doi.org/10.2967/jnumed.121.263743
J Nucl Med
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 63(11), 1659-1664
ISSN: 1535-5667
0161-5505
DOI: 10.2967/jnumed.121.263743
Popis: The objective of this study was to evaluate the safety and feasibility of (99m)Tc-based prostate-specific membrane antigen (PSMA) robot-assisted–radioguided surgery to aid or improve the intraoperative detection of lymph node metastases during primary robot-assisted radical prostatectomy (RARP) for prostate cancer (PCa). Methods: Men with primary high-risk PCa (≥ cT3a, International Society of Urological Pathology (ISUP) grade group ≥ 3 or prostate-specific antigen of ≥ 15 ng/mL) with potential lymph node metastasis (Briganti nomogram risk > 10% or on preoperative imaging) were enrolled in the study. Patients underwent staging (68)Ga-PSMA PET/CT scanning. Preoperatively, a (99m)Tc-labeled PSMA ligand ((99m)Tc PSMA I&S; 500 MBq) was administered followed by SPECT/CT. A RARP including extended pelvic lymph node dissection was performed, with intraoperative tracing of PSMA-avid tissues using a prototype DROP-IN γ-probe. Resected specimens were also measured ex vivo. Histopathologic concordance with probe findings was evaluated. A radiotracer count of ≥ 1.5 times the background reference (in vivo), and ≥ 10 (absolute count) in the ex vivo setting, was considered positive. Results: Twelve patients were included (median age, 68 y, and prostate-specific antigen, 9.15 ng/mL). Most of the patients harbored ISUP 5 PCa (75%) and had avid lymph nodes on preoperative PSMA PET (64%). The DROP-IN probe aided resection of PSMA-avid (out-of-template) lymph nodes and residual disease at the prostate bed. Eleven metastatic lymph nodes were identified by the probe that were not observed on preoperative (68)Ga-PSMA PET/CT. Of the 74 extraprostatic tissue specimens that were resected, 22 (29.7%) contained PCa. The sensitivity, specificity, positive predictive value, and negative predictive value of inpatient use of the γ-probe were 76% (95% CI, 53%–92%), 69% (95% CI, 55%–81%), 50%, and 88%, respectively. Ex vivo, the diagnostic accuracy was superior: 76% (95% CI, 53%–92%), 96% (95% CI, 87%–99%), 89%, and 91%, respectively, for sensitivity, specificity, positive predictive value, and negative predictive value. Of the missed lymph nodes in vivo (n = 5) and ex vivo (n = 5), 90% were micrometastasis (≤3 mm). No complications greater than Clavien–Dindo Grade I occurred. Conclusion: Robot-assisted (99m)Tc-based PSMA-radioguided surgery is feasible and safe in the primary setting, optimizing the detection of nodal metastases at the time of RARP and extended pelvic lymph node dissection. Further improvement of the detector technology may optimize the capabilities of robot-assisted (99m)Tc-based PSMA-radioguided surgery.
Databáze: OpenAIRE
Externí odkaz: